Myelodysplastic Syndrome (MDS)/CMML

Intermediate and High Risk

Untreated MDS

Relapsed/Refractory

Myelodysplastic Syndrome (MDS)

IDH1

Chronic Myelomonocytic Leukemia (CMML)

For transplant

IDH1

Untreated MDS

IRB#16867 Study coming soon (treatment naïve high risk MDS)

IRB#15619 Phase 1/2 Vadastuximab Tailrine (SGN-CD33A) plus Standard of care chemo in intermediate to high risk MDS

IRB#15953 Phase 2 treatment with SY-1425, a selective Retinoic Acid Receptor Alpha Agonist

IRB#16142 Ph1 Oral AG-120 treatment

IRB#11076 Phase I with LOR-253

IRB#15977 Non Treatment National MDS Study (ECOG/ACRIN)

IRB#15993 Study coming soon (relapsed/refractory MDS)

IRB#16142 Ph1 Oral AG-120 treatment

Key

- Open for Enrollment
- In Development
- Enrollment on Hold

www.ohsu.edu/cancer

1/25/17